- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
More data needed on AstraZeneca COVID vaccine trials: WHO scientists
![More data needed on AstraZeneca COVID vaccine trials: WHO scientists More data needed on AstraZeneca COVID vaccine trials: WHO scientists](https://medicaldialogues.in/h-upload/2020/09/04/750x450_133986-astrazeneca.webp)
London: The World Health Organization's top scientist says more data is needed to determine if the coronavirus vaccine developed by Oxford University and AstraZeneca works.
Oxford and AstraZeneca reported on Monday that their vaccine appeared 62% effective in people who received two doses and 90% effective when volunteers were given a half dose followed by a full dose. They later acknowledged a manufacturing issue had resulted in a half dose mistakenly being administered as the first dose to some participants.
Dr Soumya Swaminathan, WHO's chief scientist, said at a Friday media briefing that "the numbers are still too small to really come to any definitive conclusions". In the study, 2,741 people got a half dose followed by a full dose while 8,895 people got two full doses. None of the people in the half-dose regimen were over age 55. "It's hard to compare these two groups," she said.
She said the agency had heard AstraZeneca would like to conduct a full study testing the half dose followed by a full-dose regimen, noting that the other ongoing research evaluating the vaccine uses two full doses.
Read also: COVID vaccine maker AstraZeneca targeted by suspected North Korean hackers
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story